Enhanced external counterpulsation treatment on the incidence of acute kidney injury after coronary angiography contrast agent

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068290

Enrollment

Unknown

Registered

2023-02-14

Start date

2023-02-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-induced acute kidney injure

Interventions

postoperative EECP group:postoperative EECP

Preoperative EECP group:Preoperative EECP

Preoperative and postoperative EECP group:Preoperative and postoperative EECP

Control group:aquation

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Undergoing elective coronary angiography examination indication.

Exclusion criteria

Exclusion criteria: 1. EECP contraindications: acute heart failure; With hemodynamic instability of malignant arrhythmia; Severe aortic valve closure is not complete; Active phlebitis, venous thrombosis; Severe lower limb vascular occlusive diseases; All sorts of hemorrhagic disease or bleeding tendency; Dissecting aneurysm; Counterpulsation position infection; Malignant tumor; During pregnancy or breastfeeding women; 2. Coronary angiography contraindicated: contrast contrast sensitivity test positive and iodine allergy; Allergy sufferer, such as bronchial asthma, severe atopic dermatitis, food allergies, etc.; Severe hepatic insufficiency; Hyperthyroidism; Women during pregnancy or lactation; Always happened in CI - AKI; 3. Continue after coronary angiography interventional treatment or related inspection: PCI, PTCA, OCT, IVUS, FFr, etc.; 4. Within a month before the coronary angiography has a history of renal toxicity drugs or food; 5. Within 1 week before coronary angiography has received angiography (including enhanced CT, etc.); 6. Have accepted renal replacement therapy, such as hemodialysis, peritoneal dialysis and kidney transplants; 7. At the same time to participate in other clinical studies.

Design outcomes

Secondary

Measure	Time frame
ß2-microglobulin;C-Reactive Protein;Complete Blood Count;	—

Primary

Measure	Time frame
creatinine;	—

Countries

China

Contacts

Public ContactLi Shunxiang

The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital

875172455@qq.com+86 183 4419 1943

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026